The Centre for Applied Neurogenetics (CAN) is able to pursue its cutting-edge research through the generous support of private and public agencies. Funding for our research comes from a variety of sources.: from federal funding (Canadian Excellence Research Chairs program, Canadian Foundation for Innovation) to disease-specific charities and partnerships with the pharmaceutical industry. Investment from the latter is directed primarily towards translational research.
Canada Excellence Research Chair Program
- Funding to help establish the Centre for Applied Neurogenetics
Leading Edge Endowment Fund
- Endowment fund to support the BC Leadership Chair in Genetic Medicine
Canadian Institutes of Health Research
- Operating grant: Molecular neuroscience of Parkinson’s Disease: Retromer (VPS35) dysfunction
- Operating grant: Implicating novel genes in familial Parkinsonism
The Peter Cundill Foundation
- Understanding Parkinsonism, FXTAS and related neurodegenerative diseases using molecular neuroscience
- Advancing the cure for Parkinson’s Disease
Michael J. Fox Foundation
- Cognitive Biomarkers: Parkinson’s disease, alpha-synuclein and cognitive medicine.
- The role of LRRK2 in dopamine modulation of striatal glutamate transmission.
- Longitudinal characterization of G2019S KI mice: Physiological and behavioral analyses of dopamine and gluatamate systems.
- Parkinson’s Progression Markers Initiative: Clinical, imaging and plasma and CSF correlates of alpha-synuclein genomic variability